title: Vioxx may go back on sale after scraping past FDA panel.
authors.forename: Meredith
authors.initials: M
authors.lastname: Wadman
mesh_terms: D000068579:Celecoxib; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence* / Q000592:standards; D004348:Drug Labeling / Q000331:legislation & jurisprudence / Q000592:standards; D006801:Humans; D007555:Isoxazoles / Q000600:supply & distribution; D007783:Lactones / Q000009:adverse effects / Q000191:economics* / Q000600:supply & distribution*; D011720:Pyrazoles / Q000600:supply & distribution; D013449:Sulfonamides / Q000600:supply & distribution; D013450:Sulfones / Q000009:adverse effects / Q000191:economics* / Q000600:supply & distribution*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*; D000096926:Benzenesulfonamides
chemical_list: D000068579:Celecoxib; D007555:Isoxazoles; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides